Key Takeaway
Activated charcoal significantly reduces systemic drug exposure even after intravenous drug administration, demonstrating its ability to interrupt enterohepatic and enteroenteric drug cycling.
Summary
This meta-analysis investigated whether activated charcoal can reduce drug exposure (measured by area under the curve, AUC) even when drugs are administered intravenously, bypassing the GI tract entirely. This is relevant because it tests charcoal's ability to intercept drugs that are secreted back into the gut after systemic circulation.
The pooled analysis found a statistically significant reduction in drug exposure with activated charcoal, supporting the concept that charcoal can bind drugs undergoing enterohepatic recirculation or intestinal secretion. This mechanism, sometimes called "gastrointestinal dialysis," suggests charcoal may have utility beyond just blocking initial oral absorption.
The findings support the use of multiple-dose activated charcoal for specific drugs that undergo significant enterohepatic cycling, though the clinical relevance varies by substance.
Methods
- Meta-analysis of controlled studies using IV drug administration followed by oral activated charcoal
- Measured drug exposure via AUC (area under the concentration-time curve)
- Pooled effect estimates across multiple drug types
- Assessed heterogeneity and publication bias
Key Results
- Activated charcoal significantly reduced AUC of IV-administered drugs
- Demonstrates charcoal can interrupt enterohepatic and enteroenteric drug cycling
- Effect size varied by drug and charcoal dosing protocol
- Supports the "gastrointestinal dialysis" mechanism for multiple-dose charcoal
Limitations
- Most studies conducted in healthy volunteers, not overdose patients
- Heterogeneity in drug types, charcoal doses, and timing protocols
- Clinical significance of AUC reductions varies by drug and overdose severity
- Limited applicability to drugs without significant enterohepatic cycling